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TBackground: Reperfusion injury continues to significantly affect patients undergo-
ing lung transplantation. Isolated lung models have demonstrated that adenosine
A2A receptor activation preserves function while decreasing inflammation. We
hypothesized that adenosine A2A receptor activation by ATL-146e during the initial
reperfusion period preserves pulmonary function and attenuates inflammation in a
porcine model of lung transplantation.
Methods: Mature pig lungs preserved with Viaspan (Barr Laboratories, Pomona, NY)
underwent 6 hours of cold ischemia before transplantation and 4 hours of reperfusion.
Animals were treated with (ATL group, n  7) and without (IR group, n  7)
ATL-146e (0.05 g kg1 · min1 ATL-146e administered intravenously for 3 hours).
With occlusion of the opposite pulmonary artery, the animal was maintained for the final
30 minutes on the allograft alone. Recipient lung physiology was monitored before
tissue evaluation of pulmonary edema (wet-to-dry weight ratio), myeloperoxidase assay,
and tissue tumor necrosis factor  by means of enzyme-linked immunosorbent assay.
Results: When the ATL group was compared with the IR group, the ATL group had
better partial pressure of carbon dioxide (43.8  4.1 vs 68.9  6.3 mm Hg, P  .01)
and partial pressure of oxygen (272.3  132.7 vs 100.1  21.4 mm Hg, P  .01).
ATL-146e–treated animals exhibited lower pulmonary artery pressures (33.6  2.1 vs
47.9 3.5 mm Hg, P .01) and mean airway pressures (16.25 0.08 vs 16.64 0.15
mm Hg, P  .04). ATL-146e–treated lungs had lower wet-to-dry ratios (5.9 0.39 vs
7.3 0.38, P .02), lower myeloperoxidase levels (2.9 105  1.2 105 vs 1.3
 104 4.0 105OD mg1 · min1, P .03), and a trend toward decreased lung
tumor necrosis factor  levels (57  12 vs 96  15 pg/mL, P  .06). The ATL group
demonstrated significantly less inflammation on histology.
Conclusion: Adenosine A2A activation during early reperfusion attenuated lung
inflammation and preserved pulmonary function in this model of lung transplanta-
tion. ATL-146e and similar compounds could play a significant role in improving
outcomes of pulmonary transplantation.
Despite improvements in lung preservation techniques and organ-specific pres-ervation solutions, ischemia-reperfusion injury after lung transplantation con-tinues to occur in 10% to 20% of recipients.1,2 Ischemia-reperfusion injury has
been shown to be clinically relevant because of increased in-hospital mortality and
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sive care unit stay, and increased cost of hospitalization.3
Furthermore, the prospect of ischemia-reperfusion injury limits
the number of acceptable organs for transplantation to less than
a third of organ donors.4 Therefore the prevention or attenua-
tion of ischemia-reperfusion injury in transplanted lungs could
result in profound effects in both those patients receiving
organs in our current system and could improve the usefulness
of marginal lung donors, thus possibly expanding the number
of suitable lungs for transplantation.
Over the past several years, lung transplantation research
has focused on prevention of lung injury by improving
preservation solutions to attenuate injury from storage and
transport of the donor organ.5 However, significant inflam-
matory reaction still occurs with reperfusion. Recent studies
have demonstrated that pharmacologic intervention at reper-
fusion rather than during the preservation period could
preserve function in spinal cord, renal, and cardiac models
of ischemia-reperfusion injury.6-9 Most important to this
study, adenosine A2A receptor activation during reperfusion
in isolated lung models improved graft function while de-
creasing cellular and molecular markers of inflamma-
tion.10,11 On the basis of these studies, activation of this
receptor is thought to have great potential in modulation of
reperfusion injury in lung transplantations. The adenosine
A2A receptor is predominantly expressed on inflammatory
cells, including neutrophils, mast cells, macrophages,
monocytes, and platelets.12 The mechanism of injury atten-
uation in ischemia and reperfusion of various organs by
activation of this receptor appears to involve attenuation of
the secondary inflammatory reaction through a purinergic
regulatory process.13 The adenosine A2A receptor is coupled
to a stimulatory G protein, which leads to an increase in
intracellular cyclic adenosine monophosphate. Increased
cyclic adenosine monophosphate through this pathway
leads to an inactivation of inflammatory cells, resulting in
reduced cytokine release, accumulation of other inflamma-
tory cells, and possibly even the modulation of cellular
immunity through impaired T-cell activity.14 Although sev-
eral inflammatory cells certainly play a role in ischemia-
reperfusion injury, this study focused on the neutrophil and
tumor necrosis factor  (TNF-) as representatives of in-
flammation.
The aim of this study was to demonstrate that the in-
flammatory response in a whole animal lung transplantation
model could be lessened and that pulmonary function would
parallel this inflammatory reduction. We hypothesized that
ATL-146e, a specific adenosine A2A receptor agonist, given
at reperfusion would both impair the inflammatory response
to lung transplantation, as demonstrated by neutrophil se-
questration and TNF- production, and preserve pulmonary
1138 The Journal of Thoracic and Cardiovascular Surgery ● Mafunctional physiology.
Methods
Animal Care
All animals received humane care in accordance with the “Guide
for care and use of Laboratory animals” published by the National
Institute of Health (National Institutes of Health publication no.
85-23, revised 1985). The Animal Care and Use Committee at the
University of Virginia reviewed and approved the protocol for this
study before experimentation.
Study Groups
Domestic swine of both sexes (18-30 kg) were randomly separated
into 2 groups (both n  7). The first group was an ischemia-
reperfusion control group (the IR group) that underwent 6 hours of
ischemia, followed by 4 hours of reperfusion. The second group
(the ATL group) underwent the same procedure but also received
ATL-146e (ATL) for the first 3 hours of reperfusion. The dosing
of ATL was based on previous experience with this drug in the
isolated lung model of ischemia-reperfusion injury, as well as
experience with this drug in the prevention of ischemic spinal cord
injury.11 A dose of 0.05 g kg1 · min1 for 3 hours was chosen
for this study because this was the optimal in vivo dose, as
determined in earlier studies on spinal cord injury.
Donor Procedure
The donor lung harvest procedure was identical for both groups.
The pigs were anesthetized with ketamine (50 mg/kg) and xylazine
(5 mg/kg). After endotracheal intubation, they were ventilated with
a volume-cycled ventilator with a 15 mL/kg tidal volume at a rate
of 10 to 16 breaths/min. The fraction of inspired oxygen was 100%
for the procedure. Pigs were anesthetized with halothane and
anticoagulated with 200 U/kg heparin sodium. A left thoracotomy
was performed to expose the heart and left lung. The inferior
pulmonary ligament was taken down before the pulmonary artery
was dissected. Prostaglandin E1 (PGE1; 10 mg/kg) was injected
directly into the main pulmonary artery. After the main pulmonary
artery was clamped with a large vascular clamp, the lung was
submerged in saline slush, and 1 L of Viaspan (Barr Laboratories,
Pomona, NY), the commercially available version of the Univer-
sity of Wisconsin solution that was being used clinically at the
time of this study, was infused from a height of 30 cm. The heart
and both lungs were excised en bloc. The left pulmonary artery and
bronchus were isolated, as well as the part of the left atrium that
received the left pulmonary veins. The rest of the heart and the
right lung were discarded. The donor lung was doubly wrapped in
a sterile bag. It was then stored in the preservation solution at 4°C
for 6 hours before implantation. This ischemic time was chosen
because previous studies had shown adequate injury for study at
this time point, and the ischemic time correlated with the clinical
scenario.15
Recipient Procedure
Recipient swine were size matched to the donor before induc-
tion with ketamine (50 mg/kg) and xylazine (5 mg/kg). The
recipient was intubated before placement on a volume ventila-
tor. After neck dissection with carotid arterial line placement
and internal jugular line placement, a pulmonary artery catheter
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TXwas floated until it wedged. Then a left thoracotomy was
performed, with exposure of both the right and left main pul-
monary arteries. A vessel loop was placed around the right
pulmonary artery to facilitate subsequent occlusion. Next a left
pneumonectomy was completed by ligating the pulmonary
veins individually before clamping the left pulmonary artery
and bronchus proximally and cutting them distally. The donor
lung was attached to the left main stem bronchus by using 4-0
Prolene sutures (Ethicon, Inc, Somerville, NJ). After confirming
an airtight bronchial anastomosis, the left pulmonary artery was
anastomosed with 5-0 Prolene sutures. Finally, the atrial cuff of
the donor was sewn to a section of the recipient left atrium
isolated with a side-biting vascular clamp by using a 4-0 Pro-
lene suture. After adequate hemostasis was achieved, the skin
was reapproximated with towel clamps for the reperfusion
period.
IR group animals were reperfused for 3.5 hours before the right
pulmonary artery was clamped, maintaining the recipient animal
on the donor lung for the final 30 minutes of reperfusion. The ATL
group underwent an identical procedure with the addition of re-
ceiving intravenous ATL-146e (0.05 g kg1 · min1) for the first
3 hours of reperfusion beginning 10 minutes before reperfusion.
After 4 hours of reperfusion, an arterial blood gas measurement
was taken. By using a pressure ventilator, ventilation parameters
were taken, including mean airway pressure, tidal volume, peak
inspiratory pressure, minute volume, and compliance. With a pul-
monary artery catheter, the cardiac output, cardiac index, pulmo-
nary artery pressure, wedge pressure, systemic vascular resistance,
and pulmonary vascular resistance were determined. The mean
arterial pressure and heart rate were also monitored throughout the
procedure. Ventilator settings were used to maintain normal pH,
PCO2, and PO2 during reperfusion in both lungs. No changes were
made once single-lung reperfusion began.
Samples were taken from the donor and recipient lung, as well
as from the left ventricle, which were both frozen in liquid nitrogen
and fixed in 10% formalin. Samples were also taken from both
lungs for the wet-to-dry weight ratios, the myeloperoxidase (MPO)
assay, and the TNF- assay. Serum samples were taken at 0, 1, 2,
3, and 4 hours of reperfusion before being frozen for the TNF-
assay.
Wet-to-Dry Weights
For wet-to-dry weight ratios, parenchymal samples of whole lungs
were taken after reperfusion. The tissue was blotted to remove
excess blood in all samples. The samples were weighed before
placement in a vacuum oven for 48 to 72 hours. The samples were
weighed daily until the weight was stable. These data were used as
an indicator of the amount of pulmonary edema. Lungs with higher
wet-to-dry ratios would be expected to have had more pulmonary
edema.
MPO Activity
Neutrophil sequestration was quantified by using a MPO activity
assay. Lung and ventricular tissue was frozen in liquid nitrogen
after the reperfusion period. The tissue was resuspended in 50
mmol/L KPO4 (pH 7.4) and then homogenized for 30 seconds at
4°C. The solution was centrifuged for 15 minutes at 15,000g
(Sorvall RC-5b Refrigerated Superspeed Cintrifuge; Kendro Lab-
The Journal of Thoracicoratory Products, Newton, Conn). The supernatant was discarded
before the pellet was resuspended in 0.5% hexadecyltrimethylam-
moniumbromide (HTAB) in 50 mmol/L KPO4 (pH 6.4). The
solution was then homogenized a second time for 90 seconds at
4°C. The solution underwent sonication and 3 freeze-thaw cycles
(alternating liquid nitrogen for 1 minute and 37°C circulating bath
for 5 minutes). The solution was centrifuged for a second time at
15,000g for 15 minutes. The supernatant was divided into 1-mL
aliquots. The assay buffer was made from 10 mg of o-diadanosine
in 1 mL of deionized water, 100 mL of H2O2, and 8.9 mL of 50
mmol/L potassium phosphate (pH 6.0). The 15 mL of supernatant
was combined with 135 mL of assay buffer and incubated at room
temperature in a 96-well flat-bottom plate. Absorbance at 460 nm
was measured over 2 minutes by means of spectrophotometry
(MRX Revelation Plate Reader; Dynex Technologies, Inc, Chan-
tilly Va). MPO activity was expressed as change in absorbance per
milligram per minute.
TNF- Assay
Lung tissue lysate was generated from a minimum of 5 mg of
tissue sample (lung wedge) in Triton X-100 lysis buffer by using
a tissue homogenizer (Fisher Scientific International, Pittsburgh,
Pa). The lysis buffer consisted of 1% Triton X-100 (Sigma-Aldrich
Corp, St Louis, Mo), 20 mmol/L Tris pH 7.4 (Sigma-Aldrich Corp,
St Louis, Mo), 150 mmol/L NaCl (Sigma-Aldrich Corp), 1
mmol/L ethylenediamine tetraacetic acid (Sigma-Aldrich Corp), 2
g/mL Leupeptin (Roche Diagnostics Corp, Indianapolis, Ind), 0.7
g/mL Pepstatin (Roche Diagnostics Corp), 100 mol/L Chymo-
statin (Roche Diagnostics Corp), and 100 mol/L Antipain (Roche
Diagnostics Corp). The samples were centrifuged at 10,000 rpm
and 0°C for 10 minutes to remove debris. The supernatant was then
aspirated and used for enzyme-linked immunosorbent assay
(ELISA). TNF- levels of lung tissue lysates and serum were
determined by using commercially available ELISA kit (Pierce
Biotechnology, Inc, Rockford, Ill), according to the manufactur-
er’s protocols. All samples were tested in duplicate and averaged.
The ELISA kit sensitivity for TNF- was 20 pg/mL. All readings
were performed on an MRX II Absorbance Reader (DYNEX
Technologies Inc). TNF- concentration was expressed in pico-
grams per milliliter.
Lung Injury Score
After tissue processing and staining for hematoxylin and eosin,
lung samples were graded by a blinded pathologist. Each sample
was graded with a lung injury score on the basis of the amount of
neutrophils, interstitial infiltrate, and alveolar edema. A modified
version of this scoring system has been used previously in an
isolated mouse model of lung ischemia and reperfusion.16 Each of
these 3 categories was given a score of 0 to 3, resulting in a
possible range of 0 for normal lung to 9 for most injured lung.
Details of the lung injury scoring are depicted in Table 1.
Statistical Analysis
All statistics were performed by an independent statistician. For
this study, a Student t test for independent samples was conducted
to compare the IR group with the ATL group.
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Physiologic
Arterial blood gases were significantly different between the
ATL and IR groups in terms of pH, PCO2, and PO2. The ATL
group’s mean pH was 7.39  0.04 compared with a more
acidotic mean pH of 7.27  0.03 in the IR group (P  .05).
ATL treatment preserved PCO2 levels compared with those
seen in the IR group (43.8  4.1 vs 68.9  6.3 mm Hg,
respectively; P  .01). Oxygenation was significantly im-
proved among animals receiving ATL (272.3  50.2 mm
Hg) compared with that of animals in the IR group (100.1
21.4 mm Hg, P  .01).
This study identified no statistically significant differ-
ence between groups in terms of mean arterial pressure,
cardiac output or index, systemic vascular resistance, or
pulmonary capillary wedge pressure. In addition, minute
volume and pulmonary compliance were similar. However,
ATL-treated animals demonstrated significantly lower mean
pulmonary artery pressures (33.6  2.14 vs 47.9  3.5 mm
Hg, P  .01) and pulmonary vascular resistance (933.1 
109.3 vs 1772.3  313.9, P  .03) than animals in the IR
group. Finally, mean airway pressures were significantly
lower in the ATL group compared with those in the IR
group (16.3  0.08 vs 16.6  0.15 mm Hg, P  .04).
Pulmonary Edema
Wet-to-dry weight ratios were determined to quantify the
amount of lung edema in the transplanted lungs. ATL-
treated donor lungs had a significantly lower mean ratio
than those of the control animals (5.88  0.31 vs 7.25 
0.38, P  .02). Both of these groups had higher values than
the mean wet-to-dry weight ratio of lungs from pigs under-
going anesthesia alone (4.70  0.09). There was also no
discernible difference between recipient (nonischemic)
lungs of the ATL and IR groups (5.62  0.27 vs 5.68 
0.15, P  .85).
Neutrophil Sequestration
The MPO assay demonstrated less neutrophil sequestration
in ATL animals compared with that in animals in the IR
group (2.9  105  1.2  105 vs 1.3  104  4.0 
TABLE 1. Lung injury score description
Category 0 1 2 3
Neutrophils per high-
powered field
5 6-10 11-20 20
Alveolar edema:
edema per
alveolar area
5% 6%-25% 25%-50% 50%
Interstitial infiltrate None Minimal Moderate Severe
This is the scoring system used to evaluate lung injury in the current study
on the basis of neutrophil infiltration, alveolar edema, and interstitial
edema.105 OD mg1 · min1, P  .03).
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TNF- concentrations were less than the detectable levels,
as determined by means of ELISA, in serum at 0, 1, 2, 3,
and 4 hours of reperfusion. TNF- concentrations were also
not detectable in animals that did not undergo pulmonary
ischemia. However, after 4 hours of reperfusion, the mean
TNF- concentration trended lower in ATL-treated animals
than in the IR group (57  12 vs 96  15 pg/mL, P  .06).
Lung Injury Score
The lung injury score was significantly lower in ATL-
treated animals compared with that in the IR group (2.00 
0.44 vs 4.57  0.87, P  .03). When broken down further,
the majority of the difference between the 2 groups
stemmed from less pulmonary neutrophil infiltration in the
ATL group compared with that in control animals (2.0 
0.3 vs 0.9  0.3, P  .02). These scores are summarized in
Table 2.
Discussion
The mechanism of lung ischemia and reperfusion is suffi-
ciently complex that precise processes of injury progression
and manipulation are poorly understood. Ischemia-reperfusion
injury stems from the interplay between ischemic injury to the
donor graft and the secondary injury from reperfusion, includ-
ing the recipient inflammatory response.17 Clinical manipula-
tion of the ischemic insult has not yet reached the point of
providing benefit to the 20% of lung transplant recipients who
experience reperfusion injury.3
Our recent research has focused on attenuation of ischemia-
reperfusion injury by means of pharmacologic intervention at
the time of reperfusion. The use of adenosine A2A agonists has
been shown to augment several specific cellular and molecular
targets that play considerable roles in the progression of this
injury. Adenosine A2A receptors are present on almost all
inflammatory cells (including neutrophils, mast cells, macro-
phages, eosinophils, platelets, and T-cells).12 In these cells
activation of this receptor is almost universally inhibitory.18
Most important to this study is the inhibition of the macro-
phage and the neutrophil. Adenosine A2A receptors are also
present on vascular smooth muscle. Activation of these vas-
cular receptors leads to muscular relaxation and vascular dila-
tation. Because both inflammation and vasoconstriction play
major roles in ischemia-reperfusion injury, this receptor would
TABLE 2. Lung injury score for ATL-treated and IR animals
ATL IR P value
Neutrophils 0.86 0.26 2.00 0.31 .016*
Alveolar edema 0.29 0.18 1.14 0.51 .12
Interstitial infiltrate 0.86 0.14 1.03 0.30 .15
Total 2.00 0.44 4.57 0.87 .027*
*Statistical significance.appear to have great potential for ameliorating this process.
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response can be targeted at numerous sites. First, resident
pulmonary macrophages play a role in early injury.19,20
Macrophage activation instigates a local inflammatory cas-
cade through the release of TNF- and proinflammatory
cytokines. At reperfusion, cellular injury leads to resident
macrophage activation, which in turn releases more inflam-
matory mediators. Ultimately, the cytokines stimulate T-cell
and neutrophil activation. The inflammatory cascade ampli-
fies into a systemic response, which overflows into further
graft injury. In fact, this inflammatory response is suffi-
ciently exaggerated that the inflammation leads to injury to
other organs, including the heart and the contralateral
lung.21,22 The overview of this process provides multiple
cellular and molecular targets for manipulation.
Recent literature on pulmonary ischemia-reperfusion in-
jury on one of these cellular targets has demonstrated the
significance of macrophage function and the reduction of
injury from macrophage impairment.19,20,23 The resident
macrophage appears to be particularly important in the early
phases of reperfusion injury. Early in reperfusion, the resi-
dent macrophage releases TNF-, leading to upregulation
of the inflammatory cascade. Reduced levels of TNF- in
tissue can demonstrate a blunted inflammatory response and
an inhibition of resident macrophage function. In an isolated
mouse model focusing on the resident pulmonary mecha-
nism of reperfusion injury, Maxey and colleagues16 dem-
onstrated that TNF- knockout mice had preserved pulmo-
nary function, impaired inflammatory response, and
preserved cytoarchitecture compared with wild-type ani-
mals. This study concluded that TNF- played a major role
in the early progression of pulmonary ischemia-reperfusion
injury. The current study demonstrated a nearly significant
trend in the reduction of TNF- levels after lung transplan-
tation. This reduction is most likely from the inactivation of
macrophages by adenosine A2A activation, but this is far
from proved here. No matter the source of TNF- affected,
there is a reduction with use of ATL-146e. This might lead
to further downregulation of the inflammatory cascade.
Although their role is limited in the first several hours
after reperfusion, neutrophils play a significant role in
ischemia-reperfusion injury.23 Numerous studies have
shown that adenosine A2A activation impairs neutrophil
function and activation in response to various modes of
injury.24-26 Isolated lung studies have demonstrated de-
creased neutrophil sequestration in lungs receiving ATL-
146e. In an isolated rabbit lung model, Ross and cowork-
ers11 demonstrated that perfusion of the ischemic lung with
an adenosine A2A receptor agonist limited the MPO activity
in the lungs within 30 minutes of reperfusion. In a similar
model with high-flow reperfusion in isolated rabbit lungs,
Fiser and associates10 showed a trend toward decreased
MPO activity in animals receiving ATL-146e compared
The Journal of Thoracicwith ischemic control animals. The reduction in neutrophil
sequestration is echoed in this study by a significant de-
crease in the MPO activity in ATL-treated animals com-
pared with activity in animals in the IR group. Furthermore,
this evidence of impaired neutrophil activation or recruit-
ment is confirmed by the histologic findings of fewer neu-
trophils in the lung tissue. The combination of molecular
and histologic data strengthens the argument of neutrophil
impairment with adenosine A2A receptor activation. This
study does not show directly that adenosine A2A receptor
activation inactivates neutrophils, but a growing body of
evidence suggests neutrophil inactivation by ATL-146e.
This study does have its limitations. With respect to
inflammation, the markers used are crude. MPO assays
alone do not prove increased neutrophil infiltration into
tissue. Moreover, increased infiltration does not prove in-
creased neutrophil activity but rather only suggests com-
partmental recruitment. However, the histologic scoring by
our pathologist tends to support the MPO findings. The
neutrophil infiltration scoring alone showed significant dif-
ferences between the groups. We believe that these 2 mark-
ers of impaired neutrophil recruitment imply that the use of
ATL in this injury does attenuate the neutrophil response to
this injury. The reperfusion period chosen for this study is
probably not optimal for identifying the peak TNF- con-
centrations in serum or tissue. Although low levels of
mRNA of TNF- and TNF- have been demonstrated very
early in the reperfusion period, the peak concentration might
occur later in the process.27,28 The TNF- data were also
limited to a trend toward lower concentrations in ATL-
treated transplant lungs compared with in that seen in lungs
of the IR group. But the trend approaches significance even
at this early time point. Despite the lack of statistical dif-
ference, we believe that ATL will indeed modulate TNF-
production in this injury, given a longer reperfusion period
and larger sample size, which we hope to show in future
studies. The short reperfusion period remains valid because
we are trying to demonstrate that early intervention during
reperfusion can preserve lung allograft function from the
deleterious effects of ischemia-reperfusion injury. Finally,
this study does not exclude other mechanisms of injury
attenuation. This study did not demonstrate any appreciable
changes in systemic hemodynamics, but the microvascula-
ture response to adenosine A2A activation has not been
studied. Even ATL-146e can reduce systemic blood pres-
sure through vasodilatation at a much higher dose than those
used in this study.29
Additionally, the idea of direct cellular protection by this
compound remains theoretical but possible. Studies in spi-
nal cord ischemia and reperfusion have found that the
functional preservation is demonstrable before any appre-
ciable increase in markers of inflammation.7 Although the
study has limitations, we believe that the conclusions re-
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prove to benefit lung transplant recipients in the future.
The ultimate goal of modulation of ischemia-reperfusion
injury remains the preservation of lung transplant function.
On the basis of our limited understanding of reperfusion
injury, inflammatory reduction should lead to improved
lung function. This study demonstrated preserved lung
function as defined by blood gases in terms of pH, oxygen-
ation, and ventilation. Pulmonary mechanics were also pre-
served, with improved pulmonary vascular resistance and
lower pulmonary artery pressures. ATL-treated animals also
had lower mean airway pressures, which were probably
exacerbated by less pulmonary edema, as indicated by wet-
to-dry weight ratios. Functionally, ATL-treated animals ex-
perienced far superior physiologic performance than ani-
mals in the IR group. These results are consistent with
previous studies in isolated lung models.10,11 Adenosine
A2A activation in the early reperfusion period improves
physiology in a fashion that parallels inflammatory
inhibition.
This study shows that in a large animal model of trans-
plantation, activation of the adenosine A2A receptor at
reperfusion can impair the inflammatory response and pre-
serve pulmonary function during the first 4 hours after
transplantation. In conclusion, the use of ATL-146e or a
similar compound can improve outcomes by reducing the
detrimental effects of ischemia-reperfusion injury on lung
transplant function.
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Discussion
Dr David Fullerton (Denver, Colo). I enjoyed your talk very
much, and I have enjoyed following the progress of your labora-
tory at the University of Virginia as you have pursued the appli-
cation of A2A receptor stimulation in a variety of models and now
into lung transplantation. I had 3 questions I wondered if you
might expand a little bit on.
First, as you pointed out in your slide, ultimately the intracel-
lular mechanism that is activated by A2A receptor stimulation is
through cyclic adenosine monophosphate (cAMP) and through
phosphokinase A. I am curious whether you might have any
thoughts on whether this is an A2A receptor–specific phenomenon
or whether it might be possible to activate phosphokinase A
through any other membrane-based receptors.
Dr Reece. There are certainly other possibilities to explore in
the manipulation of intracellular cAMP in response to injury. We
are exploring pathways to synergize the response to ATL-146e
with the addition of a phosphodiesterase inhibitor to further ac-
centuate cAMP and the resulting functional preservation. We
would never entertain the idea that we have the only substance that
can affect this mechanism, but we believe that ATL-146e effec-
tively attenuates ischemia-reperfusion injury.
Dr Fullerton. You did a nice job in your study of associating
your findings with neutrophil-mediated injury, particularly with
your MPO assays, and your work that has led up to this has
demonstrated an antineutrophil effect, if you will, of adenosine.
Could you speculate on whether there might be other mechanisms
of injury, such as an oxidative stress injury, that the adenosine
might also affect?
Dr Reece. I think that direct cellular protection with adenosine
receptor activation is definitely a possibility. The more we study
The Journal of Thoracicactivation of this receptor, the more we observe that the level of
protection might extend beyond what can be accounted for by the
reduction of anti-inflammation. We have seen this phenomenon in
the spinal cord studies, in which we believe we are limiting the
inflammation, but the animals are improving much beyond the
relative inflammatory attenuation. There could be both direct ef-
fects on the tissue because some adenosine compounds have a
preconditioning effect, and then also there is a potential for vaso-
dilatation in at least the smaller vessels, although we do not see it
in terms of our hemodynamics systemically.
Dr Fullerton. Finally, TNF is an appropriate suspect for any
sort of injury like this, and you did a nice job of demonstrating
increased tissue levels of TNF in your control group. I was curious
whether you might have looked at any other cytokines, either
proinflammatory cytokines or potentially anti-inflammatory cyto-
kines, like IL-10 for instance, which is recognized to diminish the
production of TNF.
Dr Reece. We have not looked at other inflammatory cytokines
using these models yet. We are trying to move in that direction and
are looking at mRNA signaling and upregulation of other inflam-
matory cytokines to identify where in the process of injury to
inflammation these substances are attenuating ischemia and reper-
fusion. We have no results to report at this time, but this is the
direction in which we are heading.
Dr John Chen (Honolulu, Hawaii). You studied this in a
model of lung transplantation. Can you speculate as to whether this
compound would be useful in cardiac surgery, for instance, in
reducing inflammation in cardiopulmonary bypass?
Dr Reece. There are published studies with ATL-146e in
cardiac infarction models that have shown improvement in the
reversibility of ischemic injury and the resultant function of hearts
in mice. As we have demonstrated with the spinal cord ischemia-
reperfusion attenuation, adenosine A2A receptor activation might
have a role in a wide array of organ preservation, including cardiac
transplantation, in the future.
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